Biologic therapy in pediatric inflammatory bowel disease

Patel Sonal, Jennifer Strople*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The incidence of pediatric inflammatory bowel disease (IBD) has risen over the past several decades and therapeutic strategies continue to evolve. Many unique considerations must be taken into account when selecting the optimal therapy for a pediatric IBD patient, including the effect of therapy on growth parameters, the cummulative or long-term adverse effects of treatments, and the inherently longer duration of therapy give the young age at diagnosis. Biologic agents have been used to treat pediatric IBD for several decades. This chapter reviews the biologic agents currently used to treat this population, the indications for use in pediatric Crohn’s disease (CD) and ulcerative colitis (UC), outcomes associated with these medications, including impact on growth and bone health, and adverse events, specfically malignancy risks. Strategies and recommendations for vaccination of peidatric IBD patients receiving biologic therapy are also reviewed.

Original languageEnglish (US)
Title of host publicationTreatment of Inflammatory Bowel Disease with Biologics
PublisherSpringer International Publishing
Pages163-183
Number of pages21
ISBN (Electronic)9783319602769
ISBN (Print)9783319602752
DOIs
StatePublished - Jan 1 2017

Fingerprint

Biological Therapy
Inflammatory Bowel Diseases
Pediatrics
Biological Factors
Therapeutics
Bone Development
Ulcerative Colitis
Vaccination
Incidence
Health
Growth
Population
Neoplasms

Keywords

  • Anti-TNF therapy
  • Anti-integrin therapy
  • Growth failure
  • Hepatosplenic T-cell lymphoma
  • Infliximab
  • Pediatric Crohn’s disease
  • Pediatric Ulcerative colitis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sonal, P., & Strople, J. (2017). Biologic therapy in pediatric inflammatory bowel disease. In Treatment of Inflammatory Bowel Disease with Biologics (pp. 163-183). Springer International Publishing. https://doi.org/10.1007/978-3-319-60276-9_11
Sonal, Patel ; Strople, Jennifer. / Biologic therapy in pediatric inflammatory bowel disease. Treatment of Inflammatory Bowel Disease with Biologics. Springer International Publishing, 2017. pp. 163-183
@inbook{7c8233fa6d1a49b6bcc304f5326b7518,
title = "Biologic therapy in pediatric inflammatory bowel disease",
abstract = "The incidence of pediatric inflammatory bowel disease (IBD) has risen over the past several decades and therapeutic strategies continue to evolve. Many unique considerations must be taken into account when selecting the optimal therapy for a pediatric IBD patient, including the effect of therapy on growth parameters, the cummulative or long-term adverse effects of treatments, and the inherently longer duration of therapy give the young age at diagnosis. Biologic agents have been used to treat pediatric IBD for several decades. This chapter reviews the biologic agents currently used to treat this population, the indications for use in pediatric Crohn’s disease (CD) and ulcerative colitis (UC), outcomes associated with these medications, including impact on growth and bone health, and adverse events, specfically malignancy risks. Strategies and recommendations for vaccination of peidatric IBD patients receiving biologic therapy are also reviewed.",
keywords = "Anti-TNF therapy, Anti-integrin therapy, Growth failure, Hepatosplenic T-cell lymphoma, Infliximab, Pediatric Crohn’s disease, Pediatric Ulcerative colitis",
author = "Patel Sonal and Jennifer Strople",
year = "2017",
month = "1",
day = "1",
doi = "10.1007/978-3-319-60276-9_11",
language = "English (US)",
isbn = "9783319602752",
pages = "163--183",
booktitle = "Treatment of Inflammatory Bowel Disease with Biologics",
publisher = "Springer International Publishing",

}

Sonal, P & Strople, J 2017, Biologic therapy in pediatric inflammatory bowel disease. in Treatment of Inflammatory Bowel Disease with Biologics. Springer International Publishing, pp. 163-183. https://doi.org/10.1007/978-3-319-60276-9_11

Biologic therapy in pediatric inflammatory bowel disease. / Sonal, Patel; Strople, Jennifer.

Treatment of Inflammatory Bowel Disease with Biologics. Springer International Publishing, 2017. p. 163-183.

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Biologic therapy in pediatric inflammatory bowel disease

AU - Sonal, Patel

AU - Strople, Jennifer

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The incidence of pediatric inflammatory bowel disease (IBD) has risen over the past several decades and therapeutic strategies continue to evolve. Many unique considerations must be taken into account when selecting the optimal therapy for a pediatric IBD patient, including the effect of therapy on growth parameters, the cummulative or long-term adverse effects of treatments, and the inherently longer duration of therapy give the young age at diagnosis. Biologic agents have been used to treat pediatric IBD for several decades. This chapter reviews the biologic agents currently used to treat this population, the indications for use in pediatric Crohn’s disease (CD) and ulcerative colitis (UC), outcomes associated with these medications, including impact on growth and bone health, and adverse events, specfically malignancy risks. Strategies and recommendations for vaccination of peidatric IBD patients receiving biologic therapy are also reviewed.

AB - The incidence of pediatric inflammatory bowel disease (IBD) has risen over the past several decades and therapeutic strategies continue to evolve. Many unique considerations must be taken into account when selecting the optimal therapy for a pediatric IBD patient, including the effect of therapy on growth parameters, the cummulative or long-term adverse effects of treatments, and the inherently longer duration of therapy give the young age at diagnosis. Biologic agents have been used to treat pediatric IBD for several decades. This chapter reviews the biologic agents currently used to treat this population, the indications for use in pediatric Crohn’s disease (CD) and ulcerative colitis (UC), outcomes associated with these medications, including impact on growth and bone health, and adverse events, specfically malignancy risks. Strategies and recommendations for vaccination of peidatric IBD patients receiving biologic therapy are also reviewed.

KW - Anti-TNF therapy

KW - Anti-integrin therapy

KW - Growth failure

KW - Hepatosplenic T-cell lymphoma

KW - Infliximab

KW - Pediatric Crohn’s disease

KW - Pediatric Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=85042284029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042284029&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-60276-9_11

DO - 10.1007/978-3-319-60276-9_11

M3 - Chapter

AN - SCOPUS:85042284029

SN - 9783319602752

SP - 163

EP - 183

BT - Treatment of Inflammatory Bowel Disease with Biologics

PB - Springer International Publishing

ER -

Sonal P, Strople J. Biologic therapy in pediatric inflammatory bowel disease. In Treatment of Inflammatory Bowel Disease with Biologics. Springer International Publishing. 2017. p. 163-183 https://doi.org/10.1007/978-3-319-60276-9_11